# Case Report Forms

## Lithium Orotate for Cognitive Protection Study

**Protocol**: LAHAI-LI-2026-001

---

# Form 1: Screening & Eligibility

**Participant ID**: _____________
**Screening Date**: _____________
**Screener Initials**: _____________

---

## Demographics

| Field | Response |
|-------|----------|
| Date of Birth | ____/____/________ |
| Age | _______ years |
| Sex at Birth | ☐ Male  ☐ Female |
| Gender Identity | ☐ Man  ☐ Woman  ☐ Non-binary  ☐ Prefer not to say |
| Race (select all) | ☐ White  ☐ Black  ☐ Asian  ☐ American Indian  ☐ Pacific Islander  ☐ Other: _______ |
| Ethnicity | ☐ Hispanic/Latino  ☐ Not Hispanic/Latino |
| Education | ☐ < High school  ☐ High school  ☐ Some college  ☐ Bachelor's  ☐ Graduate |
| Employment | ☐ Working  ☐ Retired  ☐ Disabled  ☐ Other: _______ |
| Living Situation | ☐ Alone  ☐ With spouse/partner  ☐ With family  ☐ Assisted living  ☐ Other |

---

## Inclusion Criteria

*All must be YES to proceed*

| # | Criterion | Response |
|---|-----------|----------|
| I1 | Age ≥ 50 years | ☐ Yes  ☐ No |
| I2 | Subjective cognitive complaints (self or informant) | ☐ Yes  ☐ No |
| I3 | MoCA score 22-26 OR subjective complaints with MoCA ≥ 22 | ☐ Yes  ☐ No |
| I4 | Able to provide informed consent | ☐ Yes  ☐ No |
| I5 | Willing to comply with study procedures | ☐ Yes  ☐ No |
| I6 | English-speaking | ☐ Yes  ☐ No |

**All inclusion criteria met?** ☐ Yes → Continue  ☐ No → STOP, Not Eligible

---

## Exclusion Criteria

*All must be NO to proceed*

| # | Criterion | Response |
|---|-----------|----------|
| E1 | Known kidney disease or eGFR < 60 | ☐ Yes  ☐ No |
| E2 | Uncontrolled or unstable thyroid condition | ☐ Yes  ☐ No |
| E3 | Current lithium use (any form) | ☐ Yes  ☐ No |
| E4 | Established dementia diagnosis | ☐ Yes  ☐ No |
| E5 | Mixed dementia (Alzheimer's + vascular) | ☐ Yes  ☐ No |
| E6 | Currently taking ACE inhibitor | ☐ Yes  ☐ No |
| E7 | Currently taking ARB (e.g., losartan) | ☐ Yes  ☐ No |
| E8 | Currently taking thiazide diuretic | ☐ Yes  ☐ No |
| E9 | Currently taking loop diuretic | ☐ Yes  ☐ No |
| E10 | Chronic NSAID use | ☐ Yes  ☐ No |
| E11 | Pregnant or planning pregnancy | ☐ Yes  ☐ No  ☐ N/A |
| E12 | Breastfeeding | ☐ Yes  ☐ No  ☐ N/A |
| E13 | Active substance use disorder | ☐ Yes  ☐ No |
| E14 | Unstable psychiatric condition | ☐ Yes  ☐ No |
| E15 | Terminal illness (< 12 months) | ☐ Yes  ☐ No |

**All exclusion criteria NO?** ☐ Yes → Continue  ☐ No → STOP, Not Eligible

---

## Medical History

### Cognitive History

| Question | Response |
|----------|----------|
| When did memory concerns begin? | _______ months/years ago |
| Who first noticed? | ☐ Self  ☐ Family  ☐ Clinician |
| Family history of dementia? | ☐ Yes  ☐ No  ☐ Unknown |
| If yes, relationship: | _______________________ |
| Prior cognitive testing? | ☐ Yes  ☐ No |
| If yes, results: | _______________________ |

### Medical Conditions

*Check all that apply*

| System | Conditions |
|--------|------------|
| Cardiovascular | ☐ Hypertension  ☐ CHF  ☐ CAD  ☐ Arrhythmia  ☐ Stroke/TIA |
| Endocrine | ☐ Diabetes  ☐ Hypothyroidism  ☐ Hyperthyroidism |
| Neurological | ☐ Parkinson's  ☐ Seizures  ☐ Head injury  ☐ Migraines |
| Psychiatric | ☐ Depression  ☐ Anxiety  ☐ Bipolar  ☐ PTSD  ☐ Other: _____ |
| Renal | ☐ CKD  ☐ Kidney stones  ☐ UTI (recurrent) |
| Other | ☐ Cancer (type: _____)  ☐ Autoimmune  ☐ Other: _____ |

---

## Current Medications

| Medication Name | Dose | Frequency | Start Date | Indication |
|-----------------|------|-----------|------------|------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

**Total medications**: _______

---

## Screening MoCA

| Domain | Score | Max |
|--------|-------|-----|
| Visuospatial/Executive | | 5 |
| Naming | | 3 |
| Attention | | 6 |
| Language | | 3 |
| Abstraction | | 2 |
| Delayed Recall | | 5 |
| Orientation | | 6 |
| **TOTAL** | | **30** |
| Education adjustment (+1 if ≤12 years) | | +1 |
| **ADJUSTED TOTAL** | | |

**MoCA Version**: ☐ 8.1  ☐ 8.2  ☐ 8.3

---

## Laboratory Orders

| Test | Ordered | Date Ordered |
|------|---------|--------------|
| Basic Metabolic Panel (BMP) | ☐ Yes | __________ |
| TSH | ☐ Yes | __________ |

**Lab facility**: _________________________

---

## Eligibility Determination

| | |
|---|---|
| **Eligible for study?** | ☐ Yes  ☐ No  ☐ Pending labs |
| **If No, reason**: | _________________________________ |
| **Baseline visit scheduled?** | ☐ Yes  Date: ____________ |
| **Screener signature** | _________________________________ |
| **Date** | _________________________________ |

---

---

# Form 2: Baseline Visit

**Participant ID**: _____________
**Visit Date**: _____________
**Assessor Initials**: _____________

---

## Laboratory Results Review

| Test | Value | Units | Normal Range | Within Normal? |
|------|-------|-------|--------------|----------------|
| Creatinine | | mg/dL | 0.7-1.3 | ☐ Yes  ☐ No |
| eGFR | | mL/min | > 60 | ☐ Yes  ☐ No |
| BUN | | mg/dL | 7-20 | ☐ Yes  ☐ No |
| TSH | | mIU/L | 0.4-4.0 | ☐ Yes  ☐ No |

**Labs confirm eligibility?** ☐ Yes → Continue  ☐ No → STOP, Not Eligible

---

## Vital Signs

| Measure | Value | Units |
|---------|-------|-------|
| Weight | | kg / lbs |
| Height | | cm / in |
| BMI | | kg/m² |
| Blood Pressure | / | mmHg |
| Heart Rate | | bpm |

---

## Cognitive Assessments

### MoCA (Repeat if > 2 weeks since screening)

| Total Score | _______ / 30 |
|-------------|--------------|

### MMSE

| Domain | Score | Max |
|--------|-------|-----|
| Orientation - Time | | 5 |
| Orientation - Place | | 5 |
| Registration | | 3 |
| Attention/Calculation | | 5 |
| Recall | | 3 |
| Language | | 8 |
| Visual Construction | | 1 |
| **TOTAL** | | **30** |

### Trail Making Test B

| Metric | Value |
|--------|-------|
| Time to completion | _______ seconds |
| Errors | _______ |
| Unable to complete | ☐ Yes  ☐ No |

---

## Mood and Quality of Life

### PHQ-9 (Depression)

| Item | Score (0-3) |
|------|-------------|
| 1. Little interest or pleasure | |
| 2. Feeling down, depressed | |
| 3. Trouble sleeping | |
| 4. Feeling tired | |
| 5. Poor appetite or overeating | |
| 6. Feeling bad about yourself | |
| 7. Trouble concentrating | |
| 8. Moving slowly or restless | |
| 9. Thoughts of self-harm | |
| **TOTAL** | / 27 |

**PHQ-9 Severity**: ☐ Minimal (0-4)  ☐ Mild (5-9)  ☐ Moderate (10-14)  ☐ Mod-Severe (15-19)  ☐ Severe (20-27)

### GAD-7 (Anxiety)

| Item | Score (0-3) |
|------|-------------|
| 1. Feeling nervous, anxious | |
| 2. Not able to stop worrying | |
| 3. Worrying too much | |
| 4. Trouble relaxing | |
| 5. Being restless | |
| 6. Easily annoyed or irritable | |
| 7. Feeling afraid | |
| **TOTAL** | / 21 |

**GAD-7 Severity**: ☐ Minimal (0-4)  ☐ Mild (5-9)  ☐ Moderate (10-14)  ☐ Severe (15-21)

---

## Supplement Dispensing

| Field | Response |
|-------|----------|
| Supplement brand | _________________________ |
| Lot number | _________________________ |
| Quantity dispensed | _______ capsules |
| Expiration date | _________________________ |
| Instructions reviewed | ☐ Yes |
| Take with food | ☐ Yes |
| Avoid dehydration | ☐ Yes |
| Report side effects | ☐ Yes |

---

## Informed Consent Confirmation

| | |
|---|---|
| Consent form signed | ☐ Yes |
| Copy given to participant | ☐ Yes |
| All questions answered | ☐ Yes |

---

## Visit Completion

| | |
|---|---|
| All baseline procedures completed | ☐ Yes  ☐ No |
| If No, explain: | _________________________________ |
| Next visit scheduled | Date: ____________ |
| Assessor signature | _________________________________ |
| Date | _________________________________ |

---

---

# Form 3: Follow-Up Visit

**Participant ID**: _____________
**Visit Type**: ☐ Month 3  ☐ Month 6  ☐ Month 12
**Visit Date**: _____________
**Assessor Initials**: _____________

---

## Adherence Assessment

| Question | Response |
|----------|----------|
| How many days per week do you take the supplement? | _______ / 7 days |
| Any missed doses in past month? | ☐ None  ☐ Few  ☐ Many |
| Pill count (if available) | _______ remaining |
| Pills expected remaining | _______ |
| Estimated adherence | _______ % |

**Adherence rating**: ☐ Excellent (≥90%)  ☐ Good (70-89%)  ☐ Fair (50-69%)  ☐ Poor (<50%)

---

## Adverse Events Since Last Visit

| AE # | Description | Start Date | Ongoing? | Severity | Related to Supplement? | Action Taken |
|------|-------------|------------|----------|----------|----------------------|--------------|
| 1 | | | ☐ Y ☐ N | ☐ Mild ☐ Mod ☐ Severe | ☐ Def ☐ Prob ☐ Poss ☐ Unlikely ☐ No | |
| 2 | | | ☐ Y ☐ N | ☐ Mild ☐ Mod ☐ Severe | ☐ Def ☐ Prob ☐ Poss ☐ Unlikely ☐ No | |
| 3 | | | ☐ Y ☐ N | ☐ Mild ☐ Mod ☐ Severe | ☐ Def ☐ Prob ☐ Poss ☐ Unlikely ☐ No | |

**Severity definitions:**
- Mild: Awareness of symptom but easily tolerated
- Moderate: Discomfort enough to interfere with usual activity
- Severe: Incapacitating, unable to work or do usual activity

**Serious Adverse Events?** ☐ No  ☐ Yes → Complete SAE form

---

## Medication Changes

| Medication | Change Type | Date | Reason |
|------------|-------------|------|--------|
| | ☐ Started  ☐ Stopped  ☐ Changed | | |
| | ☐ Started  ☐ Stopped  ☐ Changed | | |

**Any new contraindicated medications?** ☐ No  ☐ Yes → Review eligibility

---

## Laboratory Results

| Test | Value | Units | Normal Range | Change from Baseline |
|------|-------|-------|--------------|---------------------|
| Creatinine | | mg/dL | 0.7-1.3 | |
| eGFR | | mL/min | > 60 | |
| TSH | | mIU/L | 0.4-4.0 | |

**Clinically significant lab change?** ☐ No  ☐ Yes → Action: _________________

---

## Vital Signs

| Measure | Value | Change from Baseline |
|---------|-------|---------------------|
| Weight | kg / lbs | |
| Blood Pressure | / mmHg | |
| Heart Rate | bpm | |

---

## Cognitive Assessment

### MoCA

| Total Score | _______ / 30 | Change from Baseline: _______ |
|-------------|--------------|-------------------------------|

### MMSE (Month 12 only)

| Total Score | _______ / 30 | Change from Baseline: _______ |
|-------------|--------------|-------------------------------|

### Trail Making Test B (Month 12 only)

| Time | _______ seconds | Change from Baseline: _______ |
|------|-----------------|-------------------------------|

---

## Mood Assessment (Month 6 and 12 only)

### PHQ-9

| Total | _______ / 27 | Change from Baseline: _______ |
|-------|--------------|-------------------------------|

### GAD-7

| Total | _______ / 21 | Change from Baseline: _______ |
|-------|--------------|-------------------------------|

---

## Participant Global Impression

| Question | Response |
|----------|----------|
| Overall, how is your memory compared to before the study? | ☐ Much better  ☐ Somewhat better  ☐ Same  ☐ Somewhat worse  ☐ Much worse |
| How satisfied are you with the study supplement? | ☐ Very satisfied  ☐ Satisfied  ☐ Neutral  ☐ Dissatisfied  ☐ Very dissatisfied |
| Would you recommend this to others? | ☐ Definitely yes  ☐ Probably yes  ☐ Not sure  ☐ Probably no  ☐ Definitely no |

---

## Supplement Re-Supply (if applicable)

| Field | Response |
|-------|----------|
| New supply dispensed | ☐ Yes  ☐ No  ☐ N/A |
| Quantity | _______ capsules |
| Lot number | _________________________ |

---

## Visit Completion

| | |
|---|---|
| All procedures completed | ☐ Yes  ☐ No |
| If No, explain: | _________________________________ |
| Continue in study? | ☐ Yes  ☐ No → Reason: ____________ |
| Next visit scheduled | Date: ____________ |
| Assessor signature | _________________________________ |
| Date | _________________________________ |

---

---

# Form 4: Phone Check-In (Month 1 and Month 9)

**Participant ID**: _____________
**Call Date**: _____________
**Call Type**: ☐ Month 1  ☐ Month 9
**Caller Initials**: _____________

---

## Call Outcome

| Outcome | Response |
|---------|----------|
| Call completed | ☐ Yes  ☐ No (voicemail)  ☐ No (no answer) |
| If not completed, callback scheduled | Date: ____________ |

---

## Adherence

| Question | Response |
|----------|----------|
| Still taking supplement? | ☐ Yes  ☐ No |
| If No, reason: | _________________________________ |
| Days per week taking it | _______ / 7 |

---

## Tolerability

| Question | Response |
|----------|----------|
| Any side effects? | ☐ No  ☐ Yes |
| If Yes, describe: | _________________________________ |
| Severity | ☐ Mild  ☐ Moderate  ☐ Severe |
| Action needed | ☐ None  ☐ Dose reduction  ☐ MD referral  ☐ Discontinue |

---

## Medication Changes

| New medications since last contact? | ☐ No  ☐ Yes |
|-------------------------------------|-------------|
| If Yes, list: | _________________________________ |
| Any contraindicated medications? | ☐ No  ☐ Yes → Schedule visit |

---

## General Status

| Question | Response |
|----------|----------|
| Overall health | ☐ Good  ☐ Fair  ☐ Poor |
| Hospitalizations since last contact? | ☐ No  ☐ Yes → Details: ____________ |
| ER visits since last contact? | ☐ No  ☐ Yes → Details: ____________ |
| Any concerns or questions? | _________________________________ |

---

## Call Completion

| | |
|---|---|
| Participant reminded of next visit | ☐ Yes |
| Next visit date confirmed | ____________ |
| Caller signature | _________________________________ |
| Date | _________________________________ |

---

---

# Form 5: Study Completion / Early Withdrawal

**Participant ID**: _____________
**Date**: _____________
**Assessor Initials**: _____________

---

## Completion Status

| Status | Response |
|--------|----------|
| Reason for form | ☐ Completed 12 months  ☐ Early withdrawal |

---

## If Early Withdrawal

| Reason (select primary) | |
|-------------------------|---|
| ☐ Participant decision (no reason given) | |
| ☐ Side effects / intolerance | |
| ☐ New contraindicated medication | |
| ☐ New exclusionary diagnosis | |
| ☐ Lost to follow-up | |
| ☐ Death | |
| ☐ Investigator decision | |
| ☐ Other: | _________________________________ |

| Date of last supplement dose | ____________ |
| Date of last study contact | ____________ |

---

## Final Assessments (if possible)

| Assessment | Completed | Score / Value |
|------------|-----------|---------------|
| MoCA | ☐ Yes ☐ No | / 30 |
| MMSE | ☐ Yes ☐ No | / 30 |
| PHQ-9 | ☐ Yes ☐ No | / 27 |
| GAD-7 | ☐ Yes ☐ No | / 21 |
| Labs (eGFR, TSH) | ☐ Yes ☐ No | |

---

## Participant Feedback (12-month completers)

| Question | Response |
|----------|----------|
| Would you continue taking lithium orotate after the study? | ☐ Yes  ☐ No  ☐ Unsure |
| What did you like most about the study? | _________________________________ |
| What could be improved? | _________________________________ |
| Any other comments? | _________________________________ |

---

## Data Completion Check

| Category | Complete? |
|----------|-----------|
| All visit forms completed | ☐ Yes  ☐ No |
| All adverse events documented | ☐ Yes  ☐ No |
| All labs collected | ☐ Yes  ☐ No |
| Informed consent on file | ☐ Yes |
| Source documents filed | ☐ Yes |

---

## Investigator Sign-Off

| | |
|---|---|
| Participant has completed / withdrawn from study | ☐ Yes |
| All required data collected | ☐ Yes  ☐ No |
| Investigator signature | _________________________________ |
| Date | _________________________________ |

---

*Case Report Forms v1.0 — February 2026*
*Protocol LAHAI-LI-2026-001*
